CME

The American Association for Cancer Research (AACR) 105th Annual Meeting in San Diego invited discussion on the continued progress of immunotherapy for people with melanoma. This interview will review practice-changing data in melanoma, as presented at the AACR annual meeting. In particular, Dr. Flaherty will review the immune-stimulating effects of anti-ctla-4 and anti-pd-1 treatments that are evolving to improve the lives of people with melanoma. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm

CME credits: 0.25 Valid until: 04/30/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6808The most common type of sleep apnea is obstructive sleep apnea (OSA), which is estimated to affect more than 12 million Americans, over half of whom are overweight. Some studies suggest that nearly 50 percent of adult patients visiting primary care physicians are at risk for OSA, yet few are sent for testing. This activity will explore a patient's journey from diagnosis through counseling and treatment, as well as highlight what primary care physicians should look for in a patient's history to identify high-risk patients. Estimated time to complete activity: 15 minutes

Many healthcare providers are deficient in the utilization of new treatment regimens, as well as the application of prophylactic treatment vs. episodic treatment to achieve optimal quality of life. The World Federation of Hemophilia (WFH) Treatment Guidelines Working Group noted that recent advances have created a substantial need for the guidelines to be updated. This interview will include new information on hemophilia care to help providers incorporate the new findings into practice.

Many patients with fractures are not diagnosed as having osteoporosis or adequately treated to reduce the risk of future fractures. Multidisciplinary collaboration is necessary to properly diagnose and manage these patients. This discussion will focus on optimizing coordinated prevention and management strategies in patients with or at risk for osteoporotic fractures. 0.25 CME Credits

CME credits: 0.25 Valid until: 03/24/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6909Many patients with fractures are not diagnosed as having osteoporosis or adequately treated to reduce the risk of future fractures. Multidisciplinary collaboration is necessary to properly diagnose and manage these patients. This discussion will focus on optimizing coordinated prevention and management strategies in patients with or at risk for osteoporotic fractures. Estimated time to complete activity: 15 mins

Melanoma is the most aggressive form of skin cancer, and its incidence continues to increase dramatically. It is likely more than 76,000 new cases will be diagnosed in the US in 2014. This CME interview will discuss new advances in targeted and immune therapies in the treatment of patients with melanoma, including matching patients with the most effective treatment based on their presentation. 0.25 CME Credits

CME credits: 0.25 Valid until: 03/14/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6913Melanoma is the most aggressive form of skin cancer, and its incidence continues to increase dramatically. It is likely more than 76,000 new cases will be diagnosed in the US in 2014. This CME interview will discuss new advances in targeted and immune therapies in the treatment of patients with melanoma, including matching patients with the most effective treatment based on their presentation.Estimated time to complete activity: 15 minutes

While responsible for less than 10% of all skin cancers, melanoma is responsible for more than 75% of all skin cancer-related deaths. More than 9,500 people in the U.S. are likely to die from the disease in 2014. Treatment of melanoma is often associated with toxicities based on the agent used. One agent with a long history of managing melanoma is interleukin 2 or IL-2. Join us as Dr. John Kirkwood addresses anticipating and managing toxicity when treating with high-dose IL-2. 0.25 CME Credits

Melanoma is the most aggressive form of skin cancer and its incidence continues to increase dramatically. It is likely that more than 76,000 new cases will be diagnosed in the US in 2014. New therapeutic approaches are being aggressively sought that will positively impact patient quality of life and survival. Join us as Dr. John Kirkwood addresses how to sequence immunotherapies and targeted therapies to treat patients with melanoma. 0.25 CME Credits

CME credits: 0.25 Valid until: 03/10/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6912While responsible for less than 10% of all skin cancers, melanoma is responsible for more than 75% of all skin cancer-related deaths. More than 9,500 people in the U.S. are likely to die from the disease in 2014. Treatment of melanoma is often associated with toxicities based on the agent used. One agent with a long history of managing melanoma is interleukin 2 or IL-2. Join us as Dr. John Kirkwood addresses anticipating and managing toxicity when treating with high-dose IL-2. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm Estimated time to complete activity: 15 minutes

CME credits: 0.25 Valid until: 03/06/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6832Melanoma is the most aggressive form of skin cancer and its incidence continues to increase dramatically. It is likely that more than 76,000 new cases will be diagnosed in the US in 2014. New therapeutic approaches are being aggressively sought that will positively impact patient quality of life and survival. Join us as Dr. John Kirkwood addresses how to sequence immunotherapies and targeted therapies to treat patients with melanoma. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm Estimated time to complete activity: 15 minutes

CME credits: 0.25 Valid until: 03/04/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6874Hypoactive sexual desire disorder (HSDD) is the most common female sexual dysfunction, with about 10% of premenopausal women in the U.S. believed to have this condition. HSDD is consistently under-diagnosed and under-managed, due in great measure to the lack of adequate physician-patient communication on this topic. This CME interview will discuss the symptoms of HSDD and its impact on a patient's quality of life, along with the components for a comprehensive sexual history. It will also discuss causal factors for HSDD and common comorbid conditions, as well as therapeutic modalities available to manage HSDD, including their benefits and potential side effects. Estimated time to complete activity: 15 minutes

Hypoactive sexual desire disorder (HSDD) is the most common female sexual dysfunction, with about 10% of premenopausal women in the U.S. believed to have this condition. HSDD is consistently under-diagnosed and under-managed, due in great measure to the lack of adequate physician-patient communication on this topic. This CME interview will discuss the symptoms of HSDD and its impact on a patient's quality of life, along with the components for a comprehensive sexual history. It will also discuss causal factors for HSDD and common comorbid conditions, as well as therapeutic modalities available to manage HSDD, including their benefits and potential side effects. 0.25 CME Credits

CME credits: 0.50 Valid until: 03/03/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6915Join Dr. Tracy S. Cummings for this CME activity that will help practitioners better identify and manage binge eating disorder (BED). Based on recent DSM-5 changes in the diagnostic criteria for binge eating disorder (BED), it is likely that the number of patients diagnosed with BED will substantially increase. Dr. Cummings explores the prevalence of BED, along with its link to obesity, and discusses screening and treatment options based on recent research and clinical trials. Estimated time to complete activity: 30 minutes

CME credits: 0.50 Valid until: 02/28/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6899Asthma is characterized by eosinophilic airway inflammation and elevated serum immunoglobulin E (IgE) levels. Due to these pathologic features, the foundation of asthma treatment has historically been anti-inflammatory therapy with inhaled corticosteroids (ICSs). Numerous factors, in addition to IgE and eosinophils; however, likely play important roles in mediating the airway inflammatory response characteristic of asthma. ICSs are effective therapy for some patients with persistent asthma, but clinical trials have shown that even increasing doses of ICSs under carefully controlled situations does not always result in acceptable asthma control. Consequently, other classes of medications, in addition to ICSs, are recommended in those patients with more severe asthma. The class of medication most commonly used in more severe asthma, along with ICSs, is long-acting inhaled beta-2-agonists, but leukotriene modifying agents and anti-IgE monoclonal antibodies may also be used. Multiple agents are also on the horizon. As our understanding of the complex pathophysiology of asthma increases, it will enable the development of novel therapeutic approaches for patients who are not responding well to traditional treatments. Estimated time to complete activity: 30 minutes